- Stocks
- Healthcare
- NASDAQ: IONS

Price (delayed)

$48

Market cap

$7.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.67

Enterprise value

$8.1B

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and

The gross profit is up by 36% year-on-year

IONS's revenue is up by 35% YoY

IONS's quick ratio is down by 26% year-on-year but it is up by 25% since the previous quarter

The company's equity fell by 39% YoY and by 23% QoQ

The net income has declined by 17% year-on-year and by 5% since the previous quarter

What are the main financial stats of IONS

Market
Valuations
Earnings

Shares outstanding

145.97M

Market cap

$7.01B

Enterprise value

$8.1B

Price to book (P/B)

23.59

Price to sales (P/S)

9

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

10.43

Revenue

$776.62M

EBIT

-$277.31M

EBITDA

-$254.76M

Free cash flow

-$341.26M

Per share
Balance sheet
Liquidity

EPS

-$2.67

Free cash flow per share

-$2.34

Book value per share

$2.03

Revenue per share

$5.34

TBVPS

$18.99

Total assets

$2.76B

Total liabilities

$2.47B

Debt

$1.44B

Equity

$296.52M

Working capital

$2.09B

Debt to equity

4.87

Current ratio

7.37

Quick ratio

6.75

Net debt/EBITDA

-4.3

Margins
Efficiency
Dividend

EBITDA margin

-32.8%

Gross margin

98.7%

Net margin

-49.5%

Operating margin

-50.1%

Return on assets

-13.2%

Return on equity

-107.9%

Return on invested capital

-7.7%

Return on capital employed

-11.4%

Return on sales

-35.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Ionis Pharmaceuticals stock price performed over time

Intraday

1.46%

1 week

4.14%

1 month

15.66%

1 year

12.89%

YTD

-5.12%

QTD

0.71%

How have Ionis Pharmaceuticals's revenue and profit performed over time

Revenue

$776.62M

Gross profit

$766.68M

Operating income

-$389.1M

Net income

-$384.77M

Gross margin

98.7%

Net margin

-49.5%

The operating margin is up by 38% year-on-year but it has declined by 12% since the previous quarter

The gross profit is up by 36% year-on-year

IONS's revenue is up by 35% YoY

The net income has declined by 17% year-on-year and by 5% since the previous quarter

What is Ionis Pharmaceuticals's growth rate over time

What is Ionis Pharmaceuticals stock price valuation

P/E

N/A

P/B

23.59

P/S

9

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

10.43

Ionis Pharmaceuticals's EPS has decreased by 16% YoY and by 4.3% QoQ

The stock's price to book (P/B) is 134% more than its 5-year quarterly average of 10.1 and 27% more than its last 4 quarters average of 18.6

The company's equity fell by 39% YoY and by 23% QoQ

IONS's revenue is up by 35% YoY

The P/S is 10% more than the 5-year quarterly average of 8.2 but 3.2% less than the last 4 quarters average of 9.3

How efficient is Ionis Pharmaceuticals business performance

IONS's return on equity has dropped by 87% year-on-year and by 19% since the previous quarter

Ionis Pharmaceuticals's return on sales has increased by 28% YoY but it has decreased by 11% QoQ

Ionis Pharmaceuticals's ROIC has increased by 13% YoY but it has decreased by 12% from the previous quarter

IONS's return on assets is down by 6% since the previous quarter and by 3.1% year-on-year

What is IONS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IONS.

How did Ionis Pharmaceuticals financials performed over time

The total assets is 12% greater than the total liabilities

IONS's quick ratio is down by 26% year-on-year but it is up by 25% since the previous quarter

The current ratio rose by 25% since the previous quarter but it has declined by 25% year-on-year

Ionis Pharmaceuticals's debt to equity has soared by 74% YoY and by 30% from the previous quarter

The company's equity fell by 39% YoY and by 23% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.